Tagrisso is a cancer medicine used to treat non-small cell lung cancer (NSCLC). It is used in patients whose cancer cells have certain mutations (changes) in the gene for a protein called EGFR. It is used on its own: • in patients whose cancer cells have Ex19del or L858R mutations and whose cancer has not spread to other organs and has been completely removed by surgery; the medicine is then given to help prevent the cancer from coming back (adjuvant therapy); • in patients whose cancer cells have Ex19del or L858R mutations whose cancer is locally advanced (has started to spread to nearby areas) and cannot be removed by surgery, and whose disease has not worsened during or after treatment with platinum-based chemotherapy plus radiation therapy; • in patients whose cancer cells have mutations known as ‘activating mutations’ and whose cancer is advanced or has spread; Tagrisso is then given as the first treatment; • in patients whose cancer cells have T790M mutations and whose cancer is locally advanced or metastatic (has spread to other parts of the body). Tagrisso can also be used in combination with pemetrexed and platinum-based chemotherapy (other cancer medicines) as the first treatment in adults with advanced NSCLC with Ex19del or L858R mutations. Tagrisso contains the active substance osimertinib.
Therapeutic Indication
### Therapeutic indication TAGRISSO as monotherapy is indicated for: - the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (see section 5.1). - the treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum‑based chemoradiation therapy. - the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations. - the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. TAGRISSO is indicated in combination with: - pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
Therapeutic Area (MeSH)
ATC Code
L01XE
ATC Item
蛋白激酶抑制剂
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| osimertinib mesilate | N/A | 奥希替尼 |
EMA Name
Tagrisso
Medicine Name
Tagrisso
Aliases
N/A
